XVIVO Perfusion AB Invitation to attend XVIVO’s conference call regarding the presentation of the interim report January-March 2024.
GOTHENBURG, SWEDEN / ACCESSWIRE / April 8, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO’s conference call regarding the presentation of the interim report January-March 2024. The presentation will be held in English.
Time: Wednesday, April 24 at 2.00 pm. CET
If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions.
https://ir.financialhearings.com/xvivo-q1-report-2024
If you wish to participate via teleconference please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. Via the teleconference you can ask questions verbally.
https://conference.financialhearings.com/teleconference/?id=5008109
Participants from XVIVO:
Christoffer Rosenblad, CEO
Kristoffer Nordström, CFO
The press release for XVIVO’s interim report January-March 2024 will be released on April 24, 2024 at 7:30 am. CET.
Before the conference call, slides will be available at the company web page, https://www.xvivogroup.com/investors/reports-and-presentations/
April 8, 2023
Gothenburg
XVIVO Perfusion AB (publ)
For further information, please contact:
Christoffer Rosenblad, CEO, +46 73 519 21 59, e-mail: christoffer.rosenblad@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
Attachments
Conference call on Interim Report
SOURCE: XVIVO Perfusion AB
View the original press release on accesswire.com
